Abstracts tagged "COVID-19"

Abstract Number: 0110 • ACR Convergence 2021
Mortality in 2020 Due to COVID-19 in U.S. Adults with Rheumatic Diseases: Data from a Large, National, Multi-Rheumatic Disease Registry
Kaleb Michaud¹, Sofia Pedro², Rebecca Schumacher³, Mukund Kumar¹, Bryant England¹ and Alison Freifeld¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³Forward Databank, Wichita
Background/Purpose: Recent studies have detailed the excess death due to COVID-19 during the pandemic, yet few have examined these rates within a rheumatic disease population…
Abstract Number: 0457 • ACR Convergence 2021
Immunosuppression Attenuates Antibody and Neutralization Titers in Patients with Chronic Inflammatory Disease Following SARS-CoV-2 Vaccination
Michael Paley¹, Parakkal Deepak², Wooseob Kim², Monica Yang³, Alex Carividi³, Emanuel Demissie³, Alia A. El-Qunni,², Alem Haile², Katherine Huang², Baylee Kinnett², Mariel Liebeskind², Zhouming Liu², Lily E. McMorrow², Diana Paez³, Niti Pawar³, Dana Perantie², Rebecca E. Schriefer², Shannon Sides², Mahima Thapa², Sewuese Akuse⁴, Samantha Burdess², Abbey Rose², Lynne Mitchell², Salim Chahin², Matthew Ciorba², Jonathan Graf⁵, Patricia Katz³, Mehrdad Matloubian³, Jane O'Halloran², Rachel Presti², Gregory Wu², Sean Whelan², William Buchser², Lianne Gensler⁶, Mary Nakamura⁷, Ali H Ellebedy² and Alfred Kim², ¹Washington University in St. Louis, Olivette, MO, ²Washington University School of Medicine, St. Louis, MO, ³University of California San Francisco, San Francisco, CA, ⁴Washington University School of Medicine, St Louis, MO, ⁵Ucsf, San Francisco, CA, ⁶Department of Rheumatology, University of California San Francisco, San Francisco, CA, ⁷UCSF/SFVAHCS, San Francisco, CA
Background/Purpose: Individuals with chronic inflammatory diseases (CID) are frequently treated with immunosuppressive medications that can increase their risk of severe COVID-19. While novel mRNA-based SARS-CoV-2…
Abstract Number: 0880 • ACR Convergence 2021
Health Information Use by SLE Patients Pre and During COVID-19
Francesca Cardwell¹, Susan Elliott², May Choi³, Ricky Chin³, Yvan St.Pierre⁴, Leigha Rowbottom⁵, Murray Urowitz⁶, Guillermo Ruiz-Irastorza⁷, Sasha Bernatsky⁸, Michelle Petri⁹, Susan Manzi¹⁰, Christine Peschken¹¹, Rosalind Ramsey-Goldman¹², Paul R Fortin¹³, Jungmin Shin¹⁴, Sang-Cheol Bae¹⁵, Jiacai Cho¹⁶, Anselm Mak¹⁷, John Hanly¹⁸, Anca Askanase¹⁹, Juanita Romero-Diaz²⁰, Romina Nieto²¹, Bernardo A. Pons-Estel²², Ian N. Bruce²³, Daniel Wallace²⁴ and Ann Clarke⁵, ¹University of Waterloo, Burlington, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁴Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ⁷Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain, ⁸McGill University, Montréal, QC, Canada, ⁹Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁰Allegheny Health Network, Wexford, PA, ¹¹University of Manitoba, Winnipeg, MB, Canada, ¹²Northwestern University, Chicago, IL, ¹³CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹⁴Hanyang University Hospital, Seoul, Republic of Korea, ¹⁵Hanyang University Medical Center, Seoul, Republic of Korea, ¹⁶National University Health System (NUHS), Singapore, Singapore, ¹⁷National University of Singapore, Singapore, Singapore, ¹⁸Dalhousie University, Halifax, NS, Canada, ¹⁹Columbia University Medical Center, New York, NY, ²⁰Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Federal District, Mexico, ²¹Hospital Provincial de Rosario, Rosario, Argentina, ²²Grupo Oroo - Centro Regional de Enfermedades Autoinmunes y Reumticas (GO-CREAR), Rosario, Argentina, ²³University of Manchester, Manchester, United Kingdom, ²⁴Cedars-Sinai, Los Angeles, CA
Background/Purpose: The spread of COVID-19 misinformation is especially serious for individuals with complex diseases like SLE; conflicting and/or unfounded information can complicate a patient’s health…
Abstract Number: 1083 • ACR Convergence 2021
Outcomes of COVID-19 Illness in Systemic Autoinflammatory Diseases and Changes in Flares During the COVID-19 Pandemic: An International Survey
Samira Nazzar Romero¹, Lakshmi Moorthy², Jennifer Tousseau³, Sivia Lapidus⁴, Mariana Correia Marques⁵, Leanne Mansfield⁶, Marinka Twilt⁷, Grant Schulert⁸, Maria Gutierrez⁹, Saskya Angevare¹⁰, Fatma Dedeoglu¹¹ and Karen Durrant¹², ¹University of California Los Angeles, Los Angeles, CA, ²Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ³Autoinflamamtory Alliance, Lincoln, CA, ⁴The Joseph M. Sanzari Children's Hospital, Hackensack Meridian Health, Montclair, NJ, ⁵UPMC Children`s Hospital of Pittsburgh, Pittsburgh, PA, ⁶Hospital for Special Surgery, New York, NY, ⁷Alberta Children's Hospital, Calgary, AB, Canada, ⁸Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹John's Hopkins, Baltimore, MD, ¹⁰Autoinflammatory Alliance / Kaisz / ENCA as patient organizations, Amersfoort, Netherlands, ¹¹Boston Children's Hospital, Boston, MA, ¹²Autoinflammatory Alliance, San Francisco, CA
Background/Purpose: The exaggerated inflammatory responses to the SARS-CoV-2 virus and the paucity of data on COVID-19 infection risk in systemic autoinflammatory disease (SAID) patients posed…
Abstract Number: 1530 • ACR Convergence 2021
Evaluation of the Possible Different Evolution of SARS-CoV-2 Infection with Tumor Necrosis Factor Inhibitors or with Rituximab in Rheumatic Patients
Simón Ángel Sánchez-Fernández¹, Luisa Marena Rojas Vargas¹, Leticia Del Olmo Pérez², Paula Virginia García Morales¹, Adela Alía Jiménez¹, José Antonio Carrasco Fernández¹ and Sandra Masegosa Casanova³, ¹Hospital La Mancha Centro, Alcázar de San Juan, Spain, ²Hospital Nuestra Señora del Prado, Talavera de la Reina, Spain, ³Hospital General de Tomelloso, Tomelloso, Spain
Background/Purpose: To assess whether two different biological therapies (BT), tumor necrosis factor inhibitor (TNFi) and ritixumab (RTX), are related to a different course and severity…
Abstract Number: 1547 • ACR Convergence 2021
Potential Predictors of Outcome for Anakinra Treatment in COVID-19 Patients with Macrophage Activation Syndrome
Shirkhan Amikishiyev¹, Rabia Deniz², Mehmet Guven Gunver³, Sarvan Aghamuradov¹, Nevzat Koca¹, Burak Ince¹, Murat Bektas¹, Gorkem Durak⁴, Murat Kose², Mustafa Erelel⁵, Arif Atahan Çağatay⁶, Sevgi Kalayoglu Besısık⁷, Figen Esen⁵ and Ahmet Gül⁸, ¹Istanbul Faculty of Medicine, Istanbul University, Division of Rheumatology, İstanbul, Turkey, ²Istanbul Faculty of Medicine, Istanbul University, Department of Internal Medicine, İstanbul, Turkey, ³Department of Biostatistics, Istanbul Medical Faculty, İstanbul, Turkey,, Istanbul, Turkey, ⁴Istanbul Faculty of Medicine, Istanbul University, Department of Radiology, İstanbul, Turkey, ⁵Istanbul Faculty of Medicine, Istanbul University, Department of Anesthesiology, İstanbul, Turkey, ⁶Istanbul Faculty of Medicine, Istanbul University, Department of Infectious Diseases and Clinical Microbiology, İstanbul, Turkey, ⁷Istanbul Faculty of Medicine, Istanbul University, Division of Hematology and Therapeutic Apheresis Unit, İstanbul, Turkey, ⁸Division of Rheumatology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey
Background/Purpose: Coronavirus Disease 2019 (COVID-19) runs a severe course in a subset of patients with acute respiratory distress syndrome and multiorgan failure, and a hyperinflammatory…
Abstract Number: 1589 • ACR Convergence 2021
COVID-19 Vaccine Hesitancy in Rheumatology Patients
Rebecca Sadun¹, Amanda Eudy¹, Jennifer Rogers¹, Kai Sun², Lisa Criscione-Schreiber², Mithu Maheswaranathan², Jayanth Doss¹ and Megan Clowse³, ¹Duke University, Durham, NC, ²Duke University School of Medicine, Durham, NC, ³Duke University, Chapel Hill, NC
Background/Purpose: Patients with rheumatic diseases on certain immunosuppressant medications are known to be at higher risk for severe COVID-19. The ACR recommends COVID-19 vaccination for…
Abstract Number: 1606 • ACR Convergence 2021
Telemedicine for Rheumatology Care During the COVID-19 Pandemic: Patient Perceptions and Preferences
Maria I. Danila¹, Kelly Gavigan², Esteban Rivera², William Nowell², Michael George³, Jeffrey Curtis⁴, Lisa Christopher-Stine⁵, Shubhasree Banerjee³, Peter Merkel³, Kalen Young⁶, Dianne Shaw⁶, Jennifer Gordon⁶ and Shilpa Venkatachalam², ¹University of Alabama at Birmingham, Birmingham, AL, ²Global Healthy Living Foundation, Upper Nyack, NY, ³University of Pennsylvania, Philadelphia, PA, ⁴Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁵Johns Hopkins University, Baltimore, MD, ⁶Vasculitis Foundation, Kansas City, MO
Background/Purpose: The COVID-19 pandemic disrupted the delivery of medical care and resulted in a substantial uptake in telemedicine care for patients with chronic conditions, including…
Abstract Number: 1671 • ACR Convergence 2021
COVID-19 in Patients with Rheumatoid Arthritis Compared to Patients with Osteoarthritis During the Pandemic in New York City
Jonah Levine¹, Vivian Bykerk², Lindsay Lally¹, Lisa Mandl¹ and Medha Barbhaiya¹, ¹Hospital for Special Surgery, New York, NY, ²Division of Rheumatology, Hospital for Special Surgery, New York City, NY
Background/Purpose: COVID-19 in patients with rheumatoid arthritis (RA) is poorly understood. A recent study of mostly men with RA demonstrated increased COVID-19 risk in RA…
Abstract Number: 0094 • ACR Convergence 2021
Characteristics Associated with Severe Outcomes in Patients with Systemic Rheumatic Diseases Hospitalized for COVID-19 in New York City
Caroline Siegel¹, Jacky Choi², Debra D'Angelo², Paul Christos², Lindsay Lally¹, Parag Goyal², Lisa Mandl¹ and Medha Barbhaiya¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY
Background/Purpose: Patients with systemic rheumatic diseases (SRD) are potentially at increased risk of severe outcomes from SARS-CoV-2 infection due to their underlying immune dysregulation and…
Abstract Number: 0111 • ACR Convergence 2021
Risk of Hospitalization, Admission to Intensive Care and Mortality Due to COVID-19 in Patients with Rheumatic Diseases: A Population-based Matched Cohort Study
Ana Michelle Avina-Galindo¹, Shelby Marozoff¹, Zahra Fazal¹, Jessie Kwan¹, Na Lu¹, Alison Hoens², Diane Lacaille³, Jacek Kopec⁴, Hui Xie⁵ and J. Antonio Avina-Zubieta³, ¹Arthritis Research Canada, Vancouver, BC, Canada, ²Arthritis Research Canada Arthritis Patient Advisory Board, Vancouver, BC, Canada, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴University of British Columbia, Richmond, BC, Canada, ⁵Simon Fraser University, Burnaby, BC, Canada
Background/Purpose: New cases of the novel coronavirus disease (COVID-19) continue to occur even one year since the declaration of a global pandemic. Although most people…
Abstract Number: 0485 • ACR Convergence 2021
The Impact of COVID-19 on Rheumatology Trainee Health and Wellbeing: Results from the COVID-19 Global Rheumatology Alliance Trainee Survey
Kristen Young¹, Su-Ann Yeoh², Michael Putman³, Sebastian Sattui⁴, Richard Conway⁵, Elizabeth Graef⁶, Adam Killian⁷, Maximilian Konig⁸, Jeffrey Sparks⁹, Manuel Ugarte-Gil¹⁰, Laura Upton¹¹, Francis Berenbaum¹², Suleman Bhana¹³, Jonathan Hausmann¹⁴, Pedro Machado¹⁵, Philip Robinson¹⁶, Emily Sirotich¹⁷, Paul Sufka¹⁸, Jinoos Yazdany¹⁹, Jean Liew²⁰, Rebecca Grainger²¹, Zachary Wallace²² and Aruni Jayatilleke²³, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²University College London, London, United Kingdom, ³Medical College of Wisconsin, Brookfield, WI, ⁴Hospital for Special Surgery, New York, NY, ⁵St. James's University Hospital, Dublin, Ireland, ⁶Emerson Hospital, Concord, MA, ⁷George Washington University, Washington, DC, ⁸The Johns Hopkins University School of Medicine, Baltimore, MD, ⁹Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹⁰Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ¹¹Georgetown University School of Medicine, Melbourne, FL, ¹²Sorbonne Universit - hopital Saint-Antoine, Paris, France, ¹³Crystal Run Health, Montvale, NJ, ¹⁴Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ¹⁵Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ¹⁶University of Queensland School of Clinical Medicine, Brisbane, Queensland, Australia, Herston, Australia, ¹⁷McMaster University, Hamilton, ON, Canada, ¹⁸HealthPartners, Eagan, MN, ¹⁹University of California San Francisco, San Francisco, CA, ²⁰Boston University, Boston, MA, ²¹University of Otago, Wellington, New Zealand, ²²Massachusetts General Hospital, Newton, MA, ²³Temple University, Philadelphia, PA
Background/Purpose: The COVID-19 pandemic has disrupted healthcare delivery and education of physicians, including rheumatology trainees. Our objective was to assess the impact of the COVID-19…
Abstract Number: 0882 • ACR Convergence 2021
COVID-19 Impact Among Patients with Systemic Lupus Erythematosus
Jose Rubio¹, Suzanne krishfield¹ and Vasileios Kyttaris², ¹Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, ²BIDMC, Boston, MA
Background/Purpose: Initial studies of SLE patients with COVID-19 revealed an increased risk for severe disease in people with distinct demographic features such as advanced age…
Abstract Number: 1084 • ACR Convergence 2021
COVID-19 Among Patients with Inflammatory Arthropathies Participating in the RHUMADATA Clinical Database and Registry
Denis Choquette¹, Louis Bessette², Loïc Choquette Sauvageau¹, Boulos Haraoui¹, Isabelle Ferdinand¹, Frédéric Massicotte¹, Valerie Nadon¹, Jean-Pierre Pelletier¹, Jean-Pierre Raynauld¹, Marie-Anaïs Rémillard¹, Diane Sauvageau¹, Edith Villeneuve¹ and Louis Coupal³, ¹Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ²Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ³Institut de Rhumatologie de Montréal, Saint-Lambert, QC, Canada
Background/Purpose: The COVID-19 pandemic has hit the world since 2019. The province of Québec in Canada has not escaped this plague. Our goal is to…
Abstract Number: 1531 • ACR Convergence 2021
New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19
Sarah Chang¹, Allan Feng¹, Wenzhao Meng², Sokratis Apostolidis², Elisabeth Mack³, Maja Artandi¹, Linda Barman¹, Kate Bennett⁴, Saborni Chakraborty¹, Iris Chang¹, Peggie Cheung¹, Sharon Chinthrajah¹, Shaurya Dhingra¹, Evan Do¹, Amanda Finck⁴, Andrew Gaano⁴, Reinhard Gessner⁵, Heather Giannini⁴, Joyce Gonzalez⁴, Sarah Greib³, Margrit Gündisch³, Alex Hsu¹, Alex Kuo¹, Monali Manohar¹, Rong Mao¹, Indira Neeli⁶, Andreas Neubauer³, Oluwatosin Oniyide², Abigail Powell¹, Rajan Puri¹, Harald Renz³, Jeffrey Schapiro⁷, Payton Weidenbacher¹, Rich Wittman¹, Neera Ahuja¹, Ho-Ryun Chung³, Pras Jagannathan¹, Judith James⁸, Peter Kim¹, Nuala Meyer², Kari Nadeau¹, Marko Radic⁶, William Robinson⁹, Upinder Singh¹, Taia Wang¹, John Wherry⁴, Chrysanthi Skevaki³, Eline Luning Prak⁴ and Paul Utz¹⁰, ¹Stanford, San Francisco, ²University of Pennsylvania, Philadelphia, PA, ³Marburg University, Marburg, Germany, ⁴UPenn, Philadelphia, PA, ⁵University of Marburg, Marburg, Germany, ⁶UTHSC, Memphis, TN, ⁷KPNC Regional Laboratory, Berkeley, ⁸Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Stanford University, Palo Alto, CA, ¹⁰Stanford University, Stanford, CA
Background/Purpose: Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), is associated with a wide range of clinical manifestations, including autoimmune features…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].